Off-label Ruling’s Potential Fallout Is “Terrifying,” FDA’s Temple Says

If firms could promote drugs for uses not backed by well-controlled studies, it would be “a nightmare,” Temple says; AEI’s Scott Gottlieb suggests the agency might try to regulate how medicines are prescribed.